Fassnacht M, Kenn W, Allolio B
Endocrinology and Diabetes Unit, University of Wuerzburg, Germany.
J Endocrinol Invest. 2004 Apr;27(4):387-99. doi: 10.1007/BF03351068.
Discerning malignancy in adrenal tumors largely influences disease management and is, therefore, of utmost importance to both patient and physician. Clinical presentation (e.g. virilization) and baseline hormonal evaluation (e.g. high serum DHEAS) are occasionally of great value but usually provide only limited help in predicting malignancy. The probability of malignancy is clearly related to tumor size, as almost all lesions <3 cm are benign whereas a diameter of >6 cm indicates a high risk of malignancy. Computed tomography (CT) and magnetic resonance imaging (MRI) both contribute significantly to the characterization of adrenal masses. If the attenuation of a homogeneous mass with smooth border is 10 Hounsfield units or less in unenhanced CT the diagnosis of a lipid rich adenoma is established. Similarly, enhancement washout of more than 50% in CT at 10-15 min suggests a benign lesion. In MRI both rapid contrast enhancement after gadolinium followed by rapid washout and signal intensity loss using opposed-phase image in chemical shift analysis also indicate the presence of an adenoma. In contrast, adrenal carcinomas--but also pheochromocytomas--typically present as inhomogeneous lesion with intermediate-to-high intensity on T2 images in MRI. Margins and enhancement after contrast media in CT are irregular in adrenal carcinoma. Other imaging techniques either offer little additional information (NP-59 scintigraphy) or have not yet been fully established (positron emission tomography). Fine needle aspiration/cut biopsy is at present restricted to patients with a known extra-adrenal malignancy and suspected adrenal metastasis as the only evidence of disseminated disease. Adrenal tumors classified as benign undergo follow-up imaging to assess tumor growth. If an increase in diameter of >1 cm is seen, surgical removal is recommended. Even after tumor removal the diagnosis of dignity may remain difficult. Diagnostic scores together with new immunohistological markers are the methods of choice to assess malignancy. In conclusion, an interdisciplinary approach with a structured use of available diagnostic tools is needed to classify adrenal tumors correctly.
判断肾上腺肿瘤的恶性程度对疾病管理有很大影响,因此对患者和医生都至关重要。临床表现(如男性化)和基线激素评估(如血清硫酸脱氢表雄酮水平升高)偶尔很有价值,但通常在预测恶性程度方面帮助有限。恶性的可能性与肿瘤大小明显相关,几乎所有小于3 cm的病变都是良性的,而直径大于6 cm则表明恶性风险很高。计算机断层扫描(CT)和磁共振成像(MRI)对肾上腺肿块的特征描述都有很大帮助。如果在未增强CT中,边界光滑的均匀肿块的衰减值为10亨氏单位或更低,则可诊断为富含脂质的腺瘤。同样,在CT上10 - 15分钟时增强洗脱超过50%提示为良性病变。在MRI中,钆剂注射后快速对比增强随后快速洗脱以及化学位移分析中反相位图像上信号强度降低也提示腺瘤的存在。相比之下,肾上腺皮质癌——还有嗜铬细胞瘤——在MRI的T2图像上通常表现为不均匀病变,强度为中等至高。肾上腺皮质癌在CT上的边界和造影剂增强后是不规则的。其他成像技术要么提供的额外信息很少(NP - 59闪烁扫描),要么尚未完全确立(正电子发射断层扫描)。目前,细针穿刺/切割活检仅限于已知有肾上腺外恶性肿瘤且怀疑肾上腺转移是播散性疾病唯一证据的患者。分类为良性的肾上腺肿瘤需进行随访成像以评估肿瘤生长。如果直径增加超过1 cm,建议手术切除。即使肿瘤切除后,判断其性质可能仍很困难。诊断评分以及新的免疫组织化学标志物是评估恶性程度的首选方法。总之,需要采用跨学科方法,有组织地使用可用的诊断工具来正确分类肾上腺肿瘤。